Ian Pitchford

58%
Flag icon
This is why drug companies are keen to sponsor patient groups, or to exploit the media for their campaigns, as has been seen recently in the news stories singing the praises of the breast cancer drug Herceptin, or Alzheimer’s drugs of borderline efficacy. These advocacy groups demand vociferously in the media that the companies’ drugs be funded by the NHS. I know people associated with these patient advocacy groups—academics—who have spoken out and tried to change their stance, without success: because in the case of the British Alzheimer’s campaign in particular, it struck many people that ...more
Bad Science
Rate this book
Clear rating
Open Preview